INV- 404 &
INV- 405
InVasc’s 400 Series of pro-drug candidates have been designed to inhibit key biological pathways associated with atherosclerosis. Accordingly, these compounds may be useful in preventing and/or reversing plaque formation in individuals at risk for atherosclerosis. The 400 Series compounds represent a "first-in-¬class" alterative approach in the mature market for atherosclerosis currently represented by the statin class of drugs. Several compounds in the 400 Series, have demonstrated the ability to prevent or reverse the accumulation of plaque associated with atherosclerosis in preclinical models and have inhibitory activity against SREBP2, an important enzyme playing a role in the management of LDL levels in the blood. We are advancing three candidate drugs into early pharmacokinetic, bioavailability and toxicity studies. Based on these results, a single candidate will be selected for IND submission and clinical evaluation. Assuming successful toxicology and ADME studies, the IND for one of these candidates could be filed near the end of 2011.
Additionally, the 400 Series compounds have anti-inflammatory properties, as evidenced in part by their effects on preventing the activation of the transcription nuclear factor-kappa B (Nf-kB). Accordingly, these compounds may also be useful in various inflammatory disorders including but not limited to atherosclerosis, diabetes, inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis), hypertension and aging. Due to the advancing age of baby-boomers, obesity and a sedentary lifestyle within industrialized societies, the number of patients requiring cardiometabolic drug intervention continues to grow.
First-in-class drug candidates for atherosclerosis relying on a new mechanism of action
